Urinary pharmacodynamics of low-dose ciprofloxacin and ofloxacin

被引:3
|
作者
Stein, GE [1 ]
Schooley, S [1 ]
McMillan, J [1 ]
机构
[1] Michigan State Univ, Dept Med, E Lansing, MI 48824 USA
关键词
D O I
10.1016/S0732-8893(98)00002-9
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The incidence of resistant uropathogens to the fluoroquinolones is increasing, but their effectiveness in the urine against these strains is unknown. In this investigation, we studied the urinary pharmacodynamics of ciprofloxacin (100 mg) and ofloxacin (200 mg) against urinary isolates that were moderately resistant to ciprofloxacin (Escherichia coli, MIC = 4; Klebsiella pneumoniae, MIC = 4; Staphylococcus saprophyticus, MIC = 8) and ofloxacin. Seven healthy female volunteers received three doses (one dose every 12 h) of ciprofloxacin and ofloxacin in a randomized, crossover design with a 1-week washout period between regimens. Urine bactericidal activity was determined after the first and third nose of each drug. Both ciprofloxacin and ofloxacin exhibited prolonged (greater than or equal to 6 h) urine bactericidal activity against the E. coli and K. pneumoniae isolates after the first dose. No bactericidal activity was demonstrated for ciprofloxacin against the S. saprophyticus strain. In contrast, ofloxacin exhibited urine bactericidal activity for 8 it against this isolate. Similar findings were observed after the third dose, with the exception that ciprofloxacin exhibited a short period (4 h) of bactericidal activity against the S. saprophyticus strain. In summary, low-dose regimens of ciprofloxacin and ofloxacin exhibited prolonged bactericidal activity against moderately resistant strains of common bacterial uropathogens. Only ofloxacin demonstrated bactericidal activity in the urine during the first dosing interval against a moderately resistant isolate of S. saprophyticus. (C) 1998 Elsevier Science Inc.
引用
收藏
页码:261 / 265
页数:5
相关论文
共 50 条
  • [21] CONCENTRATION OF OFLOXACIN AND CIPROFLOXACIN IN HUMAN SEMEN FOLLOWING A SINGLE ORAL DOSE
    BERGER, SA
    YAVETZ, H
    PAZ, G
    GOREA, A
    HOMONNAI, Z
    JOURNAL OF UROLOGY, 1990, 144 (03): : 683 - 684
  • [22] Influence of dose on the distribution kinetics of ciprofloxacin and ofloxacin in the isolated hindlimb of the rat
    Casquero-Dorado, AC
    Colino, CI
    Martínez, MS
    Sánchez-Navarro, A
    BIOPHARMACEUTICS & DRUG DISPOSITION, 2000, 21 (08) : 313 - 319
  • [23] PREVENTION OF URINARY-TRACT INFECTION WITH LOW-DOSE NITROFURANTOIN
    BAILEY, RR
    ROBERTS, AP
    WARDENER, HE
    GOWER, PE
    LANCET, 1971, 2 (7734): : 1112 - &
  • [25] OFLOXACIN COMPARED WITH CIPROFLOXACIN IN THE TREATMENT OF COMPLICATED LOWER URINARY-TRACT INFECTIONS
    KROMANNANDERSEN, B
    SOMMER, P
    PERS, C
    LARSEN, V
    RASMUSSEN, F
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1988, 22 : 143 - 147
  • [26] EFFECT OF LOW-DOSE QUINIDINE ON ENCAINIDE PHARMACOKINETICS AND PHARMACODYNAMICS - INFLUENCE OF GENETIC-POLYMORPHISM
    FUNCKBRENTANO, C
    TURGEON, J
    WOOSLEY, RL
    RODEN, DM
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 1989, 249 (01): : 134 - 142
  • [27] The evaluation of pharmacokinetics (PK) and pharmacodynamics (PD) of low-dose methotrexate (LDMTX) in the treatment of psoriasis
    Grim, J.
    Chladek, J.
    Martinkova, J.
    Simkova, M.
    Vaneckova, J.
    Koudelkova, V.
    Nozickova, M.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2001, 15 : 68 - 68
  • [28] POPULATION PHARMACOKINETICS (PK) AND PHARMACODYNAMICS (PD) OF LOW-DOSE KETOPROFEN IN PATIENTS WITH DENTAL PAIN
    SAMBOL, NC
    LIU, CY
    COOPER, SA
    SHEINER, LB
    GREENE, JJ
    LIN, ET
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1995, 57 (02) : 165 - 165
  • [29] LOW-DOSE
    KATZ, R
    CUCINOTTA, FA
    HEALTH PHYSICS, 1995, 68 (06): : 859 - 859
  • [30] A Literature-Based Review and Analysis of the Pharmacodynamics of the Dose Frequency of Topical 0.3% Ciprofloxacin and 0.3% Ofloxacin in the Day-1 Treatment of Bacterial Keratitis
    Pearce, John Graham
    Naunton, Mark
    Maddess, Ted
    JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, 2023, 39 (01) : 17 - 26